SEC Form 4 · accession 0001643653-26-000016
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Benevich
Officer — Chief Commercial Officer
Period of report
Sep 9, 2026
Accepted (ET)
Sep 10, 2026 · 8:29 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 9, 2026 | M | 3,194 | $43.24 | A | 66,562 | D | |
| Common Stock | Sep 9, 2026 | S | 2,154 | $154.61 | D | 64,408 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF3 | $43.24 | Sep 9, 2026 | M | 3,194 | D | — | Feb 6, 2027 | Common Stock | 3,194 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F3The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.